



DIAGNOSTIC AUTOMATION, INC.

21250 Califa Street, Suite 102 and 116, Woodland Hills, California 91367 USA

Tel: (818) 591-3030 Fax: (818) 591-8383

onestep@rapidtest.com

technicalsupport@rapidtest.com

www.rapidtest.com

IVD



See external label



2°C-8°C



Σ=96 tests

REF

1200-11

Cytomegalovirus CMV IgA

REF 1200-11

Test	CMV IgA ELISA
Method	ELISA: Enzyme Linked Immunosorbent Assay
Principle	ELISA - Indirect; Antigen Coated Plate
Detection Range	Qualitative Positive; Negative control & Cut off
Sample	5ul Serum
Inter-assay C.V.	< 15%
Intra-assay C.V.	< 10%
Total Time	~ 75 min
Shelf Life	12 Months from the manufacturing date

** Laboratory results can never be the only base of a medical report. The patient history and further tests have to be taken into account*

NAME AND INTENDED USE

The DIAGNOSTIC AUTOMATION, INC. CMV IgA ELISA is intended for use in the detection of IgA antibodies to Cytomegalovirus (CMV) infection.

SUMMARY AND EXPLANATION OF THE TEST

Cytomegalovirus is a herpes virus and a leading biological factor causing congenital abnormalities and complications among those who receive massive blood transfusions and immunosuppressive therapy. About half of pregnant women who contract a primary infection spread the disease to their fetus. When acquired in-utero, the infection may cause mental retardation, blindness, and/or deafness.

Serological tests for detecting the presence of antibody to CMV can provide valuable information regarding the history of previous infection, diagnosis of active or recent infection, as well as in screening blood for transfusions in newborns and immuno-compromised recipients. The antibodies present to Cytomegalovirus may be of the IgA, IgM and IgG. The physiological function of IgA and its clinical implication is still unclear. DIAGNOSTIC AUTOMATION ELISA CMV IgA is an accurate serologic method to detect CMV IgA antibody for identification of CMV infection.

PRINCIPLE OF THE TEST

Purified CMV antigen is coated on the surface of microwells. Diluted patient serum is added to wells, and the CMV IgA specific antibody, if present, binds to the antigen. All unbound materials are washed away. After adding enzyme conjugate, it binds to the antibody-antigen complex. Excess enzyme conjugate is washed off and TMB Chromogenic Substrate is added. The enzyme conjugate catalytic reaction is stopped at a specific time. The intensity of the color generated is proportional to the amount of IgA specific antibody in the sample. The results are read by a microwell reader compared in a parallel manner with calibrator and controls.

MATERIALS PROVIDED

1. Microwell Strips: Purified CMV antigen coated wells	(12 X 8)
2. Sample Diluent: Blue Color Solution	1 vial (22 mL)
3. Calibrator: Factor Value (f) stated on label. Red Cap	1 vial (150 µL)
4. Negative control: Range stated on Label. Natural cap	1 vial (150 µL)
5. Positive control: Range Stated on label. Green Cap	1 vial (150 µL)
6. Washing Concentrate 20X:	1 bottle (50 mL)
7. Enzyme Conjugate: Red color solution	1 vial (12 mL)
8. TMB Chromogenic Substrate: Amber bottle	1 vial (12 mL)
9. Stop Solution	1 vial (12 mL)

STORAGE AND STABILITY

1. Store the kit at 2 - 8 ° C.
2. Always keep microwells tightly sealed in pouch with desiccants. We recommend you use up all wells within 4 weeks after initial opening of the pouch.
3. The reagents are stable until expiration of the kit.

Diagnostic Automation/ Cortez Diagnostics, Inc.
21250 Califa St, Suite 102 and 116, Woodland Hills, CA 91367 USA Phone: 818-591-3030, Fax : 818-591-8383
Email: onestep@rapidtest.com Website: www.rapidtest.com

4. Do not expose test reagents to heat, sun or strong light during storage or usage.

WARNINGS AND PRECAUTIONS

1. Potential biohazardous materials:
The calibrator and controls contain human source components which have been tested and found non-reactive for hepatitis B surface antigen as well as HIV antibody with FDA licensed reagents. However, as there is no test method that can offer complete assurance that HIV, Hepatitis B virus or other infectious agents are absent, these reagents should be handled at the Biosafety Level 2, as recommended in the Centers for Disease Control/National Institutes of Health manual, "Biosafety in Microbiological and Biomedical Laboratories." 1984
2. Do not pipette by mouth. Do not smoke, eat, or drink in the areas in which specimens or kit reagents are handled.
3. The components in this kit are intended for use as a integral unit. The components of different lots should not be mixed.
4. This product contains components preserved with sodium azide. Sodium azide may react with lead and copper plumbing to form explosive metal azide. On disposal, flush with a large volume of water.

SPECIMEN COLLECTION AND HANDLING

1. Collect blood specimens and separate the serum.
2. Specimens may be refrigerated at 2 - 8 °C for up to seven days or frozen for up to six months. Avoid repetitive freezing and thawing of serum sample.

PREPARATION FOR ASSAY

1. Prepare 1x washing buffer.
Prepare washing buffer by adding distilled or deionized water to 20 x wash concentrate to a final volume of 1 liter.
2. Bring all specimens and kit reagents to room temperature (20-25 °C) and gently mix.

ASSAY PROCEDURE

1. Place the desired number of coated strips into the holder.
2. Prepare 1:40 dilutions by adding 5 µl of the test samples, negative control, positive control, and calibrator to 200 µl of sample diluent. Mix well.
3. Dispense 100 µl of diluted sera, calibrator, and controls into the appropriate wells. For the reagent blank, dispense 100 µl sample diluent in 1A well position. Tap the holder to remove air bubbles from the liquid and mix well. Incubate for 30 minutes at room temperature.
4. Remove liquid from all wells. Repeat washing three times with washing buffer.
5. Dispense 100 µl of enzyme conjugate to each well and incubate for 30 minutes at room temperature.
6. Remove enzyme conjugate from all wells. Repeat washing three times with washing buffer.
7. Dispense 100 µl of TMB Chromogenic Substrate to each well and incubate for 15 minutes at room temperature.
8. Add 100 µl of Stop Solution to stop reaction.
9. **Make sure there are no air bubbles in each well before reading**
Read O.D. at 450 nm with a microwell reader.

CALCULATION OF RESULTS

1. To obtain the cut off OD value: Multiply the OD of calibrator by factor (f) printed on the label of calibrator
2. Calculate the IgA index of each determination by dividing the OD values of each sample by obtained OD value of Cut off.

For Example:

If Factor (f) is a variable value on label = 0.4.

This factor (f) is a variable value. It could be 0.35 or 0.5 etc. printed on label of calibrator.

Obtained calibrator O.D. = 1.100

Cut off O.D. = $1.100 \times 0.4 = 0.44$

Patient Sample O.D. = 0.580

IgA index = $0.580 / 0.44 = 1.32$ (Positive Result)

Patient sample O.D. = 0.320

IgA Index = $0.320 / 0.44 = 0.73$ (Negative Result)

QUALITY CONTROL

The test run may be considered valid provided the following criteria are met:

1. If the O.D. value of the Calibrator is lower than 0.250, the test is not valid and must be repeated.
2. The CMV A Index for Negative and Positive Control should be in the range stated on the labels.

INTERPRETATION

Negative: CMV A Index of less than 0.90 are negative for IgA antibody to CMV.

Equivocal: CMV A Index between 0.91 - 0.99 is equivocal. Sample should be retested.

Positive: CMV A Index of 1.0 or greater are positive for IgA antibody to CMV.

EXPECTED VALUES

Forty nine serum specimens obtained from random, asymptomatic blood donors were tested with the DIAGNOSTIC AUTOMATION ELISA CMV IgA test. Of the 49 specimens, 12 were found to be positive (24.5 %) and 37 were found to be negative (75.5 %). Of these 12 IgA positive samples were found to be IgG positive also. Prevalence may vary depending on a variety of factors such as geographical location, age, socioeconomic status, race, type of test employed, specimen collection and handling procedures, clinical and epidemiological history.

PERFORMANCE CHARACTERISTICS

Precision:

The precision of the assay was evaluated by testing three different sera of eight replicates over 3 days. The intra-assay and inter-assay C.V. are summarized below:

	Negative	Low positive	Positive
Intra-assay	8.2%	7.4%	6.3%
Inter-assay	11.2%	8.5%	6.7%

LIMITATIONS OF THE TEST

1. The test results should be used in conjunction with information available from the patient clinical evaluation and other available diagnostic procedures.
2. The results of specimens from immunosuppressed patients may be difficult to interpret.
3. Positive test results may not be valid in persons who have received blood transfusions or other blood products within the past several months.

REFERENCES

1. Voler, A., J.E. Bidwell, et al. Manual of clinical immunology. Chapter 69. Rose, N. and Friedman, H. eds. Am. Soc. Microbiol. p.506, 1985.
2. Cremer, N.E. Antibodies in serodiagnosis of viral infection. p. 73. In Lennett E.H. ed. Laboratory diagnosis of viral infection. MerceL Dekker, Inc., New York, 1985.
3. Starr, S.E. and H.M. Friedman. "Human CMV." Chapter 65. In Manual of Clin. Microbiol., 4th ed., Lennett, E.H. et al ed. Am. Soc. Microbiol. pp. 771-719, 1985.

Date Adopted	2017-04-07
REF 1200-11	DAI-CMV IgA



DIAGNOSTIC AUTOMATION, INC.

21250 Califa Street, Suite 102 and 116, Woodland Hills, California 91367 USA

Tel: (818) 591-3030 Fax: (818) 591-8383

ISO 13485-2003



Revision Date: 2016-06-15